Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non‐small cell lung cancer
Authors:
Open Access
- 30 August 2004
- journal article
- clinical trial
- Published by Wiley in Cancer Science
- Vol. 95 (8) , 691-695
Abstract
To determine the recommended phase II dose of vinorelbine in combination with cisplatin and thoracic radiotherapy (TRT) in patients with unresectable stage III non‐small cell lung cancer (NSCLC), 18 patients received cisplatin (80 μg/m2) on day 1 and vinorelbine (20 μg/m2 in level 1, and 25 μg/m2 in level 2) on days 1 and 8 every 4 weeks for 4 cycles. TRT consisted of a single dose of 2 Gy once daily for 3 weeks followed by a rest of 4 days, and then the same TRT for 3 weeks to a total dose of 60 Gy. Fifteen (83%) patients received 60 Gy of TRT and 14 (78%) patients received 4 cycles of chemotherapy. Ten (77%) of 13 patients at level 1 and all 5 patients at level 2 developed grade 3‐4 neutro‐penia. Four (31%) patients at level 1 and 3 (60%) patients at level 2 developed grade 3‐4 infection. None developed ≥grade 3 esophagitis or lung toxicity. Dose‐limiting toxicity was noted in 33% of the patients in level 1 and in 60% of the patients in level 2. The overall response rate (95% confidence interval) was 83% (59–96%) with 15 partial responses. The median survival time was 30.4 months, and the 1‐year, 2‐year, and 3‐year survival rates were 72%, 61%, and 50%, respectively. In conclusion, the recommended dose is the level 1 dose, and this regimen is feasible and promising in patients with stage III NSCLC.Keywords
This publication has 15 references indexed in Scilit:
- Guidelines on Treatment of Stage IIIB Non-small Cell Lung Cancer*Chest, 2003
- Randomized Phase II Study of Cisplatin With Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431Journal of Clinical Oncology, 2002
- A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancerLung Cancer, 2002
- A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer.Japanese Journal of Clinical Oncology, 2001
- Novel combination chemotherapy in the treatment of non-small cell lung cancerExpert Opinion on Pharmacotherapy, 2000
- Bacterial Meningitis Observed in a Phase I Trial of Vinorelbine, Cisplatin and Thoracic Radiotherapy for Non-small Cell Lung Cancer: Report of a Case and Discussion on Dose-limiting ToxicityJapanese Journal of Clinical Oncology, 2000
- Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: Long-term follow-up results. Japan Clinical Oncology Group Protocol 8902Annals of Oncology, 2000
- Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Mitomycin, Vindesine, and Cisplatin in Unresectable Stage III Non–Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC)Annals of Oncology, 1996
- Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancerLung Cancer, 1996